Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Assets (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Current Assets data on record, last reported at $1.0 billion in Q4 2025.

  • For Q4 2025, Current Assets rose 28.63% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 28.63%, while the annual FY2025 figure was $1.0 billion, 28.63% up from the prior year.
  • Current Assets reached $1.0 billion in Q4 2025 per APLS's latest filing, up from $990.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.1 billion in Q1 2022 and bottomed at $475.4 million in Q3 2021.
  • Average Current Assets over 5 years is $826.8 million, with a median of $817.7 million recorded in 2021.
  • Peak YoY movement for Current Assets: crashed 35.96% in 2021, then surged 74.99% in 2022.
  • A 5-year view of Current Assets shows it stood at $824.0 million in 2021, then fell by 12.68% to $719.5 million in 2022, then grew by 6.51% to $766.3 million in 2023, then grew by 2.95% to $789.0 million in 2024, then grew by 28.63% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $1.0 billion in Q4 2025, $990.7 million in Q3 2025, and $755.6 million in Q2 2025.